Auriga Research Private Ltd, a Contract Research Organisation (CRO) and an extension of Arbro Pharmaceuticals, has entered into a strategic partnership with the San Francisco Research Institute (SFRI), a US-based healthcare research and innovation organisation.

The collaboration aims to strengthen global clinical research capabilities, promote AI-integrated healthcare solutions, and expand access to compliant wellness products across India, the United States, and Africa.

Auriga, known for its expertise in clinical studies, regulatory affairs, formulation development, claims substantiation, and market expansion, will bring its strong infrastructure and regional knowledge across India and Asia to the table. 

SFRI, on the other hand, will contribute its global reach across North America, Europe, and Africa, along with expertise in digital health and AI-enabled solutions.

Under the agreement, the two organisations will jointly conduct clinical trials leveraging AI for patient recruitment, monitoring, and data analytics.

Auriga will lead clinical operations, data management, and regulatory execution in India, while SFRI will oversee client engagement and market growth in the US, Japan, and Europe. Auriga will also provide eCRF systems, analytics tools, and Indian IT vendor support for global trials.

Commenting on the partnership, Dr. Saurabh Arora, Managing Director of Auriga Research, stated, "This strategic partnership with San Francisco Research Institute reflects our commitment to advancing global standards in clinical research and healthcare innovation.”

“By leveraging our strengths in regulatory science, AI-driven trials, and product development, we aim to expand access to safe, effective, and globally compliant health solutions across India, the US, and Africa. It will also help identify untapped opportunities in North America, Europe, Asia-Pacific, and other emerging markets,” he added.

SFRI will facilitate Auriga's expansion into African markets by connecting the company with key marketers and public health agencies. Additionally, SFRI will provide strategic support in regulatory affairs, public health collaborations, and commercial partnerships in regions such as Nigeria and the United States. This includes assisting with product registrations through national health authorities, linking Auriga with distributors and marketing partners, and actively supporting sales outreach and supply chain development.

Dr. John Ademola, CEO of SFRI, commented, "This partnership combines Auriga’s clinical research expertise with our strengths in AI and regulatory capabilities to accelerate the development of compliant, patient-centric health innovations.”

“It marks a strategic step toward bridging global regulatory ecosystems and scaling evidence-based wellness solutions across geographies by managing regulatory submissions and ensuring compliance with agencies such as the FDA, EFSA, TGA, and others,” he added.

The Memorandum of Understanding (MoU) outlines several key initiatives, including:

• Co-development of AI-based platforms for research, compliance, and market readiness.

• Regulatory support for product launches in India, the US, and Africa.

• Joint promotion and distribution of wellness brands such as SNEC30 and Ningen, with SFRI focusing on the US and African markets.

• Business development leadership by Auriga in Asia and by SFRI in North America and Africa.

• Joint training programs on global standards like Good Clinical Practices (GCP), Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP), Good Documentation Practices (GDP), and other auditing and compliance standards specific to healthcare, pharmaceuticals, and regulatory science.

• Collaborative development of new formulations and wellness products for global markets.

• Joint applications for grants and funded clinical research projects

The two organisations will also scale up their research training programs through both digital and in-person formats, co-develop new products, and pursue government and foundation-backed healthcare projects to increase their global impact.

Auriga currently operates five advanced laboratories in India, including two USFDA-inspected and one WHO-prequalified facility, offering end-to-end solutions to pharmaceutical, nutraceutical, cosmetic, and medical device companies.

SFRI remains focused on driving innovation in clinical development, product innovation, and AI-powered healthcare solutions.